| Company Name: |
Shanghai Raise Chemical Technology Co.,Ltd
|
| Tel: |
15026594951 |
| Email: |
rs@raise-chem.com |
| Products Intro: |
Product Name:1H-Pyrrole-2,5-dione, 3,4-dichloro-1-[(2,4-dimethoxyphenyl)methyl]-
CAS:342416-30-2
Purity:97% HPLC Package:1g;5g
|
| Company Name: |
Suzhou Zhixin Biotechnology Co., Ltd.
|
| Tel: |
0512-65118909 15162312715 |
| Email: |
sales@szzxbio.com |
| Products Intro: |
Product Name:IRES-C11
CAS:342416-30-2
Purity:98%+ Package:1g;10g;100g
|
| Company Name: |
Shanghai?Medlife?Pharm-Tech?Co.,?Ltd
|
| Tel: |
021-59167510 18117107507 |
| Email: |
vip@med-life.cn |
| Products Intro: |
Product Name:IRES-C11
CAS:342416-30-2
Purity:>=99% Package:10mg;5mg;100mg;200mg;10mM*1mLinDMSO;25mg;50mg
|
|
| | IRES-C11 Basic information |
| Product Name: | IRES-C11 | | Synonyms: | IRES-C11;1H-Pyrrole-2,5-dione, 3,4-dichloro-1-[(2,4-dimethoxyphenyl)methyl]-;3,4-Dichloro-1-(2,4-dimethoxybenzyl)-1H-pyrrole-2,5-dione | | CAS: | 342416-30-2 | | MF: | C13H11Cl2NO4 | | MW: | 316.14 | | EINECS: | | | Product Categories: | | | Mol File: | 342416-30-2.mol |  |
| | IRES-C11 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO : 250 mg/mL (790.79 mM; Need ultrasonic) | | form | Solid | | color | Light yellow to yellow |
| | IRES-C11 Usage And Synthesis |
| Biological Activity | IRES-C11 is a spectfic c-MYC internal ribosome entry site (IRES) translation inhibitor. IRES-C11 blocks the interaction of a requisite c-MYC IRES trans-acting factor, heterogeneous nuclear ribonucleoprotein A1, with its IRES. IRES-C11 does not inhibits BAG-1, XIAP and p53 IRESes[1][2].
IRES-C11 blocks cyclin D1 IRES-dependent initiation and demonstrates synergistic anti-glioblastoma properties when combined with the mechanistic target of mTOR PP242[1].IRES-C11 (50 nM) significantly inhibits both cyclin D1 and c-MYC IRES activity. IRES-C11 treatment induces a significant shift in both cyclin D1 and c-MYC mRNA to monosomal/nonribosomal fractions, whereas actin mRNA distribution is unaffected. IRES-C11 inhibits both cyclin D1 and c-MYC IRES-mediated mRNA translation, leading to reductions in protein levels.Mechanistic studies with IRES-C11 reveal binding of the inhibitors within the UP1 fragment of heterogeneous nuclear ribonucleoprotein A1. | | References | [1]. Brent Holmes, et al. Mechanistic Target of Rapamycin (mTOR) Inhibition Synergizes with Reduced Internal Ribosome Entry Site (IRES)-mediated Translation of Cyclin D1 and c-MYC mRNAs to Treat Glioblastoma. J Biol Chem. 2016 Jul 1;291(27):14146-14159.[2]. Y Shi, et al. Therapeutic potential of targeting IRES-dependent c-myc translation in multiple myeloma cells during ER stress. Oncogene. 2016 Feb 25;35(8):1015-24. |
| | IRES-C11 Preparation Products And Raw materials |
|